TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions
Neuro Oncol
.
2022 Jun 1;24(6):1008-1009.
doi: 10.1093/neuonc/noac048.
Authors
Ross Mangum
1
,
Donald Williams Parsons
2
3
4
5
Affiliations
1
Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona, USA.
2
Department of Pediatrics, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas, USA.
3
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
4
Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA.
5
The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
PMID:
35178549
PMCID:
PMC9159445
DOI:
10.1093/neuonc/noac048
No abstract available
Publication types
Editorial
Comment
MeSH terms
Adult
Central Nervous System Neoplasms* / drug therapy
Child
Humans
Pyrazoles
Pyrimidines*
Substances
Pyrazoles
Pyrimidines
larotrectinib